A new retrospective study of patient medical records suggests that men with prostate cancer who are treated with testosterone-lowering drugs are twice as likely to develop dementia within five years as prostate cancer patients ...
Oct 13, 2016
0
36
(HealthDay)—Hormone therapy for prostate cancer might dramatically increase a man's risk of developing Alzheimer's disease, a large-scale analysis of health data suggests.
Dec 8, 2015
0
59
Researchers have identified a sub-group of cells that could contribute to prostate cancer recurrence, opening up new ways to treat the disease, which claims more than 3000 lives a year in Australia.
May 29, 2013
0
0
Scientists have discovered two separate genetic 'signatures' for prostate cancer that appear to be able to predict the severity of the disease, leading to hopes that in future, accuracy of prognosis and treatment of the disease ...
Oct 8, 2012
0
0
For patients with locally advanced prostate cancer, combined treatment with chemotherapy and hormonal therapy offers extended control of prostate-specific antigen (PSA) levels, compared to hormonal therapy alone, according ...
Apr 17, 2024
0
2
A team of UCLA Health Jonsson Comprehensive Cancer Center investigators has shown the combination of a short course of powerful and intense hormonal therapy with targeted radiation is safe and effective in treating people ...
Mar 18, 2024
0
39
Researchers at the University of Chicago Medicine Comprehensive Cancer Center established "proof-of-concept" for a new treatment approach that was able to effectively treat the most aggressive forms of prostate cancer. The ...
Sep 18, 2023
0
8
For metastatic castration-sensitive prostate cancer (mCSPC), overall survival and progression-free survival are similar for Black and White patients receiving first- or second-generation androgen receptor pathway inhibitors ...
Aug 4, 2023
0
35
A new research paper titled "Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer" ...
Jun 20, 2023
0
7
For patients with noncastrate advanced prostate cancer, docetaxel, abiraterone, enzalutamide, apalutamide, or darolutamide are each recommended as standards of care with androgen deprivation therapy (ADT), and doublet therapy ...
Apr 12, 2023
0
9
